title: Hodgkin's disease in adults. Part II.
abstract: The development of a secondary cancer is an often fatal and therefore devastating complication of the successful therapy of Hodgkin's disease. The risk of developing a secondary cancer is not the same for all patients, nor is it the same for all treatments. In 1993, treatment decisions are complicated because there are often a number of management approaches that can effectively eradicate Hodgkin's disease. Certain subgroups can be treated safely with more limited therapy. Patients with peripheral IA disease experience excellent survival following involved field radiotherapy alone without staging laparotomy. Early-stage patients with good prognostic factors can be treated with radiotherapy or chemotherapy alone after a discussion of the short and long-term risks of both approaches. If unfavorable prognostic factors are present or if the patient has IIIA disease, we favor chemotherapy alone while others may employ combined modality therapy, a treatment strategy we reserve for patients with massive mediastinal disease. For advanced-stage disease, full-dose combination chemotherapy with a regimen that is familiar to the oncologist should be given. The addition of radiotherapy in this setting has not been shown to be of benefit. Each treatment strategy has to consider the individual patient and their likelihood of developing one of the complications, fatal or otherwise, of treatment. Although secondary complications must be considered in the initial strategy, unfounded fears about toxicity should not detract from delivery of therapy that has the greatest chance of cure while at the same time minimizing the risk to the patient.
authors.affiliation: Clinical Services Program, National Cancer Institute, Frederick Cancer Research and Development Center, MD 21702-1201.
authors.forename: W J
authors.initials: WJ
authors.lastname: Urba
authors.forename: D L
authors.initials: DL
authors.lastname: Longo
mesh_terms: D006689:Hodgkin Disease / Q000150:complications* / Q000628:therapy*; D006801:Humans; D016609:Neoplasms, Second Primary; D016879:Salvage Therapy